Evofem Biosciences, Inc. (EVFM) company profile
Close on Oct 19, 2026Market cap $42.93MP/E –Yield –
About Evofem Biosciences
Pharmaceutical Preparations, SIC 2834
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing products in women's health. The company's commercial portfolio includes PHEXX (formerly known as PHEXXI), a hormone-free lactic acid, citric acid, and potassium bitartrate vaginal gel prescribed for contraception, and SOLOSEC (secnidazole) 2g oral granules. Evofem sells and markets its pharmaceutical offerings primarily through commercial distribution channels, with revenue and receivables heavily concentrated among three principal customers that constitute its primary purchasers.
The company operates domestically within the United States. Its principal executive offices and corporate headquarters are located in San Diego, California.
Summary of the business section of Evofem Biosciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Evofem Biosciences, Inc.
- Founded
- 1980
- Headquarters
- San Diego, CA
- Address
- 12400 High Bluff Drive, Suite 600 92130
- Phone
- (858) 550-1900
- Website
- evofem.com
- Employees
- 29, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BPM LLP, Sacramento, California
Stock & identifiers
- Ticker
- EVFM
- Former tickers
- NEOT until Feb 26, 2018
- Exchange
- OTC
- IPO date
- Nov 20, 2014
- Shares outstanding
- 133M, Aug 12, 2026
- Public float
- $1.20M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-125 reverse, May 18, 2023; 1-for-15 reverse, May 6, 2022; 1-for-6 reverse, Jan 18, 2018
- SEC CIK
- 1618835
- CUSIP
- 30048L302
- ISIN
- US30048L3024
- FIGI
- BBG0026ZG450
- Share class FIGI
- BBG0026ZG469
- LEI
- 5493007VAGG43TIEJW57
- EIN
- 20-8527075
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Evofem Biosciences's leadership is listed in its proxy statement, last filed Oct 29, 2025.
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 | $1.18M | $1.18M | $695.26K | $0 | – |
| FY2023 | $1.52M | $1.53M | $309.23K | $1 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2024
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Other | Total | vs. prior year |
|---|---|---|---|---|---|
| Saundra Pelletier Chief Executive Officer | $579.83K | $579.83K | $18.18K | $1.18M | -23% |
| Ivy Zhang Chief Financial Officer and Secretary | $450.00K | $243.75K | $1.51K | $695.26K | +58% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Nov 20, 2014
- Offer price
- $14.00
- Securities offered
- 4,650,000
- Gross proceeds
- $65.10M
- Exchange
- Nasdaq
- First trading day
- Nov 20, 2014
- First-day close
- $12.00-14.3%
- Lock-up ends (est.)
- May 19, 2015
“ The initial public offering price is $14.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“of February 28, 2026, we had a total of 29 full-time employees.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?